Alemtuzumab for multiple sclerosis

Willis, Mark ORCID: https://orcid.org/0000-0003-3024-6063 and Robertson, Neil ORCID: https://orcid.org/0000-0002-5409-4909 2016. Alemtuzumab for multiple sclerosis. Current Neurology and Neuroscience Reports 16 , 84. 10.1007/s11910-016-0685-y

Preview

PDF - Published Version Available under License Creative Commons Attribution. Download (741kB) | Preview

Abstract

Alemtuzumab is a humanised anti-CD52 monoclonal antibody approved for use in active, relapsing multiple sclerosis (MS). Administration results in a rapid depletion of circulating lymphocytes with a subsequent beneficial immune reconstitution. Early open-label experience and recent clinical trials have demonstrated a dramatic effect on relapse rates as well as a positive effect on radiological disease outcomes and disability measures. Despite a mechanism of action that results in profound lymphopaenia, opportunistic infections are rarely seen and no excess association with malignancy has been identified. However, acquired autoimmune disease (AID) is a common adverse event following treatment, necessitating rigorous monitoring in order to facilitate prompt detection and management. Despite this issue, a unique dosing schedule and durability of effect make alemtuzumab a welcome addition to currently available treatment options for MS.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Schools > Medicine Research Institutes & Centres > MRC Centre for Neuropsychiatric Genetics and Genomics (CNGG)
Subjects:	R Medicine > R Medicine (General)
Additional Information:	This article is distributed under the terms of the Creative Commons Attribution 4.0 International License
Publisher:	SpringerLink
ISSN:	1528-4042
Date of First Compliant Deposit:	10 November 2016
Date of Acceptance:	1 August 2016
Last Modified:	12 May 2023 12:39
URI:	https://orca.cardiff.ac.uk/id/eprint/95967

Citation Data

Cited 32 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item